Skip to content
TickerMagic

Kopran Limited

KOPRANNSEHealthcare
₹267.05
+1.12 (+0.42%) · EOD 2026-11-20

Our verdict

Strong Buy

Financial trend (100/100) does the heavy lifting; quality (47/100) is the drag.

Buy zoneHealth D
Quality 47Momentum 94Value 83Trend 100The Spark ↓

Our fair value

Undervalued by 25%
₹334.61up 25.30%
Price ₹267Range ₹134 – ₹523

Buy-below (20% margin of safety): ₹267.68

The bottom line

Kopran Limited earns a Strong Buy from TickerMagic, with a blended score of 78/100. On 37.4x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. The price is about 8% below its 52-week high of ₹290.9 and 151% above the low of ₹106.22. Financial health scores 35/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 7/9. It clears 10 of 13 investability checks, with durability 47, valuation 74 and momentum 94 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹334.61up 25.30%
Undervalued by 25%
Price ₹267.05Range ₹133.53–₹522.99
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹267.68.

1-year price

EOD · 2026-11-20
1D
up 0.42%
1W
down 4.58%
1M
down 4.03%
3M
up 32.52%
6M
up 57.71%
1Y
—

52-week range

-8.20% from the 52-week high.

Trend check
Above 50-DMA₹263Above 200-DMA₹189

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Strong Buy78
D
Financial health 35/100
Altman Z 2.39 · Grey zone

Piotroski F-score 7/9 — quality of earnings & balance sheet.

Our scores

Durability47
Valuation74
Momentum94

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 10 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Fail: ROE above 15%: 4.9%
  • Pass: Low debt (D/E < 0.5): 0.29x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 36%
  • Pass: Earnings growing: 95%
  • Fail: Net margin ≥ 10%: 3.8%
  • Pass: Current ratio > 1.5: 1.51
  • Pass: Below our fair value
  • Pass: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Fail: Altman Z in safe zone: Z 2.39
  • Pass: Piotroski ≥ 7: 7/9

Quarterly results

Revenue · 1Q2019
₹91 Cr
Net profit
₹8 Cr
Margin
8%
4Q2018
1Q2019
Revenue Net profitLatest revenue QoQ -14%

Shareholding

  • Promoter50.2%
  • Institutions0.2%
  • Public & other49.6%

Promoter holding via insider stake; institutional via reported holdings.

Superstar investors in Kopran Limited

Named in the company's June 2026 shareholding filing with the exchanges.

All superstar portfolios →

Key fundamentals

Market cap
₹960 Cr
P/E ratio
37.4
P/B ratio
1.81
EPS (TTM)
₹5.32
ROE
4.9%
Debt / Equity
0.29x
Profit margin
3.8%
Free cash flow
₹6 Cr
52-week high
₹290.9
-8.20% from high
52-week low
₹106.22
Dividend yield
1.5%
Beta
0.86
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • High Piotroski quality score (7/9).

Opportunities

  • Earnings growing (95% YoY).
  • Revenue growing (36% YoY).
  • Trading in our value buy zone versus sector peers.
  • Trades ~25% below our estimated fair value.

Bear case

Weaknesses

  • Low return on equity (4.9%).

About Kopran Limited

Kopran Limited is an integrated pharmaceutical company that develops, manufactures, and markets active pharmaceutical ingredients and finished dosage forms in India and internationally. The company produces tablets, capsules, syrups, dry powders, suspensions, and injectables in both branded and generic formulations across therapeutic categories including macrolides, antibacterials, anticonvulsants, and antihypertensives.

Kopran Limited — frequently asked questions

Is Kopran Limited a buy, hold or sell?

TickerMagic currently rates Kopran Limited (KOPRAN) a Strong Buy, based on a blended score of 78/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Kopran Limited's fair value?

Our blended DCF and relative-valuation model estimates Kopran Limited's fair value at about ₹334.61, versus a current price of ₹267.05 — roughly 25% upside. On that basis the stock looks undervalued by 25%.

Is Kopran Limited financially healthy?

Kopran Limited scores 35/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 7/9.

How has Kopran Limited's share price performed?

Kopran Limited is up 33% over three months, and last traded at ₹267.05. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.